TYRA Tyra Biosciences Inc
Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Tyra Biosciences (TYRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·1mo ago
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors PR Newswire CARLSBAD, Calif., Jan. 29, 2025...
PR Newswire·8mo ago
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) Tyra Biosciences Receives IND Clearance from FDA to Proceed...
PR Newswire·8mo ago
Tyra Biosciences to Present at Upcoming Investor Conferences
Tyra Biosciences to Present at Upcoming Investor Conferences Tyra Biosciences to Present at Upcoming Investor Conferences PR Newswire CARLSBAD, Calif., Nov. 13, 2024 CARLSBAD, Calif., Nov. 13, 2024...
PR Newswire·10mo ago
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights PR Newswire CARLSBAD, Calif., Nov. 7, 2024...
PR Newswire·11mo ago
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) Tyra Biosciences Receives IND Clearance from FDA to Proceed with...
PR Newswire·11mo ago
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial...
PR Newswire·11mo ago
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET Tyra Biosciences to Host Conference Call on Interim Clinical...
PR Newswire·11mo ago
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
Tyra Biosciences receives an upgrade from BofA, raising the price target to $31. The upgrade follows promising preclinical data for TYRA-300 and increased sales projections for metastatic urothelial...
Benzinga·11mo ago
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer...
PR Newswire·11mo ago